# BTOG 2020 Programme

Continuing Professional Development – Accreditation approved
The Royal College of Pathologists for 13 CPD Credits
RCSI Faculty of Radiologists for 17.25 CPD Credits
(Accepted by all Irish Postgraduate Medical Training Bodies)
The Royal College of Surgeons of England for 16.5 CPD credits
The Federation of the Royal Colleges of Physicians of the United Kingdom for 13 CPD Credits

## Wednesday 29th January 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Registration Opens &amp; Refreshments</td>
<td>Ground Floor Conference Foyer</td>
</tr>
<tr>
<td></td>
<td>The BTOG Desk is available for registration/information throughout BTOG 2020.</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>11:00 – 14:30 BTOG Parallel Symposia (3)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>BTOG Translational Therapeutics Symposium</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session 1</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Stephen Finn (IE) and James Spicer (UK)</td>
<td>Herbert</td>
</tr>
<tr>
<td></td>
<td>15 minutes + 7 minutes discussion per speaker</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Immune evasion as a therapeutic target in NSCLC</td>
<td>Celine Mascaux (FR)</td>
</tr>
<tr>
<td>11:22</td>
<td>National Lung MATRIX trial: what have we learned?</td>
<td>Gary Middleton (UK)</td>
</tr>
<tr>
<td>11:44</td>
<td>Checkpoint inhibitor resistance and how to overcome it?</td>
<td>Ken O’Byrne (AU)</td>
</tr>
<tr>
<td>12:06</td>
<td>Chemo-I.O, I.O-I.O, or I.O-mono: which is correct?</td>
<td>Benjamin Besse (FR)</td>
</tr>
<tr>
<td>12:30</td>
<td><strong>12:30 – 13:00 Lunch and Platinum Exhibition</strong></td>
<td>Ground Floor Conference Foyer</td>
</tr>
<tr>
<td>13:00</td>
<td><strong>Session 2</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Samreen Ahmed (UK) and Michaela Higgins (IE)</td>
<td>Herbert</td>
</tr>
<tr>
<td></td>
<td>15 minutes + 7 minutes discussion per speaker</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>ctDNA for MRD: is it clinically relevant?</td>
<td>Alexandra Pender (UK)</td>
</tr>
<tr>
<td>13:22</td>
<td>How to manage osimertinib acquired resistance?</td>
<td>Natasha Leighl (CA)</td>
</tr>
<tr>
<td>13:44</td>
<td>MET, RET, ETc: what new targets are actionable</td>
<td>Stephen Liu (US)</td>
</tr>
<tr>
<td>14:06</td>
<td>Translational therapeutic strategies for SCLC</td>
<td>Fiona Blackhall (UK)</td>
</tr>
<tr>
<td>14:30</td>
<td><strong>14:30 – 15:00 Refreshments and Platinum Exhibition</strong></td>
<td>Ground Floor Conference Foyer</td>
</tr>
</tbody>
</table>

*F Final Version – the programme is subject to change/availability*
Wednesday 29th January 2020

BTOG Respiratory Medicine & Radiology Symposium  

Session 1  Horizon Scanning in Lung Cancer  
Chairs: Rachel Benamore (UK) and Sadia Anwar (UK)  
11:00 Is whole-body MR the future for lung cancer staging?  
11:30 What is the future for e-cigarettes? Looking back on 2019 from NEJM to lung injury epidemic  
12:00 Will bronchoscopists treat lung cancer in the future? Bronchoscopic ablation of lung tumours.  

12:30 – 13:00 Lunch and Platinum Exhibition  

Session 2  Horizon scanning in Mesothelioma & Exercise Oncology  
Chairs: Rebecca Duerden (UK) and Selina Tsim (UK)  
13:00 MR & the future of mesothelioma imaging; staging, tumour volume, RECIST and more.  
13:30 Will thoracoscopists treat mesothelioma in the future? Intra-pleural therapy for mesothelioma  
14:00 Cancer and exercise: Should clinicians prescribe physical activity?  

14:30 – 15:00 Refreshments and Platinum Exhibition  

BTOG Radiotherapy Symposium  

Session 1  Brain Metastases Revisited  
Chairs: Jason Lester (UK) and Stephen Harrow (UK)  
11:00 Welcome  
11:05 What is the role of SRS in TKI & IO era?  
11:25 Debate: ‘WBRT for NSCLC & PCI for SCLC no longer have a role’  
Rebuttal 5 mins each  
12:05 Brain Metastases Expert MDT: Challenging cases discussion  

12:30 – 13:00 Lunch and Platinum Exhibition  

Final Version – the programme is subject to change/availability
Wednesday 29th January 2020

Session 2  Practice Changing & Changing Practice in NSCLC
Chairs:    David Gilligan (UK) and Fiona McDonald (UK)
13:00    England data in stage I & III NSCLC: Where do we go from here?    Susan Harden (AU)
13:15    Royal College of Radiologists Consensus Summary    Ceri Powell (UK)
13:25    State of the Art Radiotherapy for NSCLC    Walter Curran (US)
14:00    UK Lung RT    Matthew Hatton (UK)
14.10    Challenging stage III case    Neeraj Bhalla (UK)
14:20    Challenging oligo-metastatic case discussion    Tony Pope (UK)

14:30 – 15:00 Refreshments and Platinum Exhibition

13:00 – 17:00 BTOG 2020 Advocates Meeting – Meeting Room 9, 1st Floor
Open to professional advocate attendees/by invitation only

15:00 – 19:45 Sponsored Satellite Symposia
45 minutes per satellite symposium

15:00    Satellite symposium sponsored by Takeda
16:00    Satellite symposium sponsored by Takeda
17:00    Satellite symposium sponsored by BMS
18:00    Satellite symposium sponsored by Roche
19:00    Satellite symposium sponsored by AstraZeneca
19:45    Close

20:00 – 21:30 BTOG Welcome Reception – Dress code: Smart/Casual

F Final Version – the programme is subject to change/availability
### Thursday 30th January 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 07:30 | Registration Opens & Refreshments  
The BTOG Desk is available for registration/information throughout BTOG 2020 |
| 08:10 - 08:50 | Sponsored Satellite Symposia  
08:10 Satellite symposium sponsored by Pfizer |
| 09:10 – 10:50 | Session 1  
09:10 Welcome - BTOG  
09:20 NCRI  
09:30 ETOP  
09:40 EORTC  
**Session 1** Plenary Session  
**Chairs:** Denis Talbot (UK) and Tom Newsom-Davis (UK)  
20 minutes + 10 minutes discussion per speaker |
| 09:50 | Lung cancer: a personal perspective and call to action  
**Presenter:** James Brokenshire (UK) |
| 10:20 | Advanced NSCLC: how should we treat it in 2020?  
**Presenter:** Luis Paz-Ares (ES) |
| 10:50 – 11:20 | Refreshments, Exhibition and Posters |
| 11:20 – 13:00 | Sessions 2 & 3  
**Session 2**  
**Chairs:** David Gonzales (UK) and Martin Forster (UK)  
11:20 How is the UK performing in molecular testing?  
**Presenter:** Neal Navani (UK)  
11:35 The current and future of NHS molecular diagnostics  
**Presenter:** Angela George (UK)  
11:50 Panel discussion |
| 12:10 | Introduction  
**Presenter:** Matthew Callister (UK) and Jackie Fenemore (UK) |
| 12:12 | Sustained lung cancer mortality reduction following a symptom awareness campaign  
**Presenter:** Christopher Marshall (UK) |
| 12:23 | An autoethnographic study to explore “meet the Lung CNS” as stated within The National Optimal Lung Cancer Pathway (NOLCP) guidance: recommendations for best practice  
**Presenter:** Alice Bobat (UK) |
| 12:34 | Neutrophil Lymphocyte ratio as a prognostic marker in patients treated with Curative intent radiotherapy for NSCLC  
**Presenter:** Anshu Punjabi (UK) |
| 12:45 | “Uncertain” Resection Margins in NSCLC: Single Institution Evaluation of Proposed IASLC Criteria  
**Presenter:** Hannah Gleeson (UK) |
| 12:56 | Closing comments |
| 13:00 | Close |
Thursday 30th January 2020

<table>
<thead>
<tr>
<th>13:00 – 14:00 Lunch, Exhibition and Posters</th>
<th>Ground Floor Conference Foyer</th>
</tr>
</thead>
</table>

### 13:10 - 13:50 Sponsored Satellite Symposia

13:10 Satellite symposium sponsored by Roche

### 14:00 – 15:30 Session 4: Improving the Cure Rate

Session 4

**Chairs:** Alan Kirk (UK) and Karen Clayton (UK) and Emma O'Dowd (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Small scar is best: VATS learnings from VIOLET</td>
<td>Eric Lim (UK)</td>
</tr>
<tr>
<td>14:15</td>
<td>No scar is best: SBRT for early lung cancer</td>
<td>Kevin Franks (UK)</td>
</tr>
<tr>
<td>14:30</td>
<td>N2 NSCLC: surgery is gold standard</td>
<td>John Edwards (UK)</td>
</tr>
<tr>
<td>14:45</td>
<td>N2 NSCLC: immunotherapy is the new gold standard</td>
<td>Neil Bayman (UK)</td>
</tr>
<tr>
<td>15:00</td>
<td>Panel and audience discussion</td>
<td></td>
</tr>
</tbody>
</table>

### 15:30 – 16:00 Refreshments, Exhibition and Posters

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>

F Final Version – the programme is subject to change/availability
Thursday 30th January 2020

16:00 – 17:00 Session 5

BTOG Poster Presentation Session
Your presence is required in front of your poster to discuss with poster judges and delegates as follows:
16:00 – 16:30 odd poster numbers
16:30 – 17:00 even poster numbers

17:00 – 18:00 Session 6

BTOG/LCNUK Nursing Session
Chairs: Jackie Fenemore (UK) and Janelle Yorke (UK)
17:00 Introduction and RIG (Research Interest Group) update Janelle Yorke (UK)
17:10 Findings from the Patient Experience study on concurrent chemo-radiation for patients with inoperable stage 3 NSCLC Insight Study Jackie Fenemore (UK)
17:25 Prehab for lung cancer treatment - what is the standard of care? Amy Kerr (UK)
17:40 The development of a prehabilitation service in the oncology setting Pamela Rose (UK)
17:55 Questions
18:00 Close

19:30 – 20:00 BTOG Reception

20:00 – 23:00 18th Annual BTOG 2020 Conference Dinner
Dress code: Gents - lounge suit and tie or black tie / Ladies - cocktail wear
The conference dinner is ticket only and must be pre-booked and includes presentation of the BTOG Lifetime Achievement Award 2020 and poster awards.
**Friday 31st January 2020**

08:45  Roy Castle Lung Cancer Foundation Grants  David Gilligan (UK)
08:52  UKLCC Report: Access Matters  Michael Peake (UK)

**09:00 – 11:00 Session 7**

**Session 7**

**Chairs:** Matthew Callister (UK) and Louise Brown (UK)

09:00  How can we investigate and stage patients quicker?  David Baldwin (UK)
09:20  How should diagnostic bundles be delivered in the UK?  Matthew Evison (UK)
09:40  How can MDTs function better?  Paul Beckett (UK)
10:00  How can we stop missing cancers?  Michael Crawford (UK)
10:20  Panel and audience discussion

**10:30 – 11:00 Refreshments, Exhibition and Posters**

**11:00 – 12:30 Session 8**

**Session 8**

**Chairs:** Barry Laird (UK) and Josie Roberts (UK)

11:00  Best supportive care advanced lung cancer: who, when and what?  Joanna Bowden (UK)
11:15  Exercise and nutrition in patients with incurable cancer: a randomised phase II trial  Charlie Hall (UK)
11:30  How and when to use immune checkpoint inhibitors in SCLC  Brian Clark (UK)
11:45  Current and future drug treatments for mesothelioma  Paul Baas (NL)
12:00  Panel and audience discussion

**12:30 – 13:30 Lunch, Exhibition and Posters**

**13:10 - 13:50 Sponsored Satellite Symposia**

13:10  Satellite symposium sponsored by Guardant Health

---

F Final Version – the programme is subject to change/availability
14:00 - 14:45 Session 9 – Parallel Sessions (2)

Session 9  NCRI LOcoRegional Diagnosis (LORD) Subgroup Update
14:00  Chair and open – update of the portfolio  Mary O’Brien (UK)
14:10  New radiotherapy studies and ideas for the group  Corinne Faivre-Finn (UK)
14:20  New surgical studies and ideas for the group  Karen Harrison-Phipps (UK)
14:30  Survivorship issues  Lynn Calman (UK)
14:40  Discussion
14:45  Close

Session 9  NCRI Mesothelioma Subgroup Update
14:00  Chair and open – update of the portfolio  Peter Szlosarek (UK)
14:05  BEAT-meso update  Sanjay Popat (UK)
14:10  Molecular targeted studies  Peter Szlosarek (UK)
14:20  Surgical studies  Robert Rintoul (UK)
14:30  ASSESS-meso  Anna Bibby (UK)
14:40  Discussion
14:45  Close

14:45 - 15:30 Session 10 – Parallel Sessions (2)

Session 10  NCRI Advanced Disease Subgroup Update
14:45  Chair and open – update of the portfolio  Fiona Blackhall (UK)
14:55  Progressing frailty research in advanced lung cancer  Fabio Gomes (UK)/Alastair Greystoke (UK)
15:10  Feasibility of Exercise Intervention in Lung Cancer: Next STEPS  Samreen Ahmed (UK)
15:25  Discussion
15:30  Close

Session 10  NCRI Screening & Early Diagnosis Subgroup Update
14:45  Chair and Open – portfolio update  Philip Crosbie (UK)
14:50  Electrocautery for the prevention of lung cancer (EARL) trial  Sam Janes (UK)
15:00  Lung cancer in survivors of teenager and young adult cancers  Robert Rintoul (UK)/Michael Hawkins (UK)
15:15  Integrating research alongside the NHS England Lung Health Check pilots  Richard Lee (UK)
15:30  Close